Friday, 23 March 2018

EMA panel for conditional OK to Clovis's ovarian cancer drug

(Reuters) - A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)